Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405031 | 0.90 | SIRT1 (0.51) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4400503 | 0.87 | ALDH1A1 (0.43) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14194790 | 0.85 | SIRT1 (0.45) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4403582 | 0.84 | SIRT1 (0.45) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4409867 | 0.82 | KDM4E (0.44) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4395705 | 0.80 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13593171 | 0.78 | TUBB4A (0.45) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5664019 | 0.77 | TUBB4A (0.45) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4329236 | 0.77 | TUBB4A (0.52) | SIRT1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4401484 | 0.76 | KDM4E (0.52) | SIRT1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390029-B1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2009-12-16 | — | — | EP | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-6710068-B2 | PHENYLSULFONYLINODLES USEFUL FOR THE TREATMENT OF HIV IN HUMANS AND OTHER HOST ANIMALS | IDENIX PHARMACEUTICALS, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | SIRT1 210/4885TUBB4A 321/4885TUBB 326/4885 |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | SIRT1 210/4885TUBB4A 321/4885TUBB 326/4885 |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | SIRT1 210/4885TUBB4A 321/4885TUBB 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.